H. Hugh Fudenberg – författare
Visar alla böcker från författaren H. Hugh Fudenberg. Handla med fri frakt och snabb leverans.
3 produkter
3 produkter
351 kr
Tillfälligt slut
The field of immunogenetics has advanced rapidly in the past few years, with the application of DNA sequencing, gene cloning and DNA/RNA hybridization techniques, and new understanding of the major histocompatibility complex. This has required a thorough upgrading of this textbook, and in addition the authors have included a new chapter on immunodeficiency.
556 kr
Skickas inom 10-15 vardagar
On May 14-16, 1982, a group of scientists met in Viareggio, Italy to present ideas, and exchange relevant data on current approaches on immunomodulators. We felt that the embodiment of the substance of that international symposium into this volume will be beneficial in keeping both clinicians and basic scientists abreast of the latest exciting developments in this rapidly accelerating field. We hope that the publication of this series of papers by an international panel of experts will enhance the nature of future inves t igat ive stud ies with such ent it ies . Under the rubric of immunology, it is obvious that such a term as "immunomodulation" could be construed as being all encompassing. However, it is intriguing that the immune modulators touched on in these sessions can be subcategorized into about five broad groups. Almost all substances, excepting those entities that are immuno logically inert, will have some modulating effects on immunity. From the coarse adjustment of antibody feedback inhibition upon cellular limnunity to the subtle finesse envisioned in Jerne's idiotypic network and s'lppressor T cells, immunomodulators attempt to either magnify or diminish those responses that are normally elicited by antigen. The broad groups - thymic hormones, D.L.E., Interferon, drugs, and the use of bacterial products appear to be at the forefront of much of the pioneering work on immunomodulation.
620 kr
Skickas inom 10-15 vardagar
The world is on the threshold of a great new industrial revolution, a 1 scientific-industrial revolution. Recombinant DNA technology and hybridoma technology ("monoclonal antibodies") have already pro vided unique investment opportunities for venture capitalists. Hence published reports of biomedical research are no longer restricted to scientific journals, but now appear regularly not only in weekly news 2 magazines like Time and U. S. News & World Report,3 but also in the financial sections of The New York Times,4 The Wall Street Journal,S 6 8 Business Week, Fortune,7 and The Economist, as well as in such stock 9 market advisory publications as New Issues and Inc. (The Magazine for Growing Companies). 10 These publications now appear to be as impor tant to biomedical scientists in keeping abreast of new scientific devel opments in biotechnology as is Current Contents. (The costs of health cost provision and of fundamental biomedical research are now also being followed by such media. ) Conversely, Wall Street financial bro kers increasingly no longer confine their reading to economic journals but are also perusing Nature,ll Science,12 and Science N 13 for infor ews mation on both fiscal and scientific advances in these areas. It is obvious that the information explosion in biotechnology is crossing traditional boundaries (e. g. , ref. 14). This volume is the second of several that are intended to inform both the biomedical community and interested intelligent laymen of the political and economic implications of biomedical research.